Research in the News

Respiratory failure is the leading cause of death after cervical spinal cord injury. Most people with high cervical SCI require ventilator support because nerve pathways from the brainstem's breathing rhythm generators to the diaphragm are interrupted. Epidural stimulation — delivering electrical pulses to the spinal cord via electrodes implanted on the epidural surface [the space between the vertebra and the spinal cord membrane] — has shown remarkable results for motor recovery, but its application to breathing has been far less explored. A 2026 preprint by Dale, Mickle, Peñaloza-Aponte, and Brennan argues that current pacing strategies override brainstem rhythm generators rather than working with them, limiting adaptability and rehabilitation potential. Their work maps ascending spinal pathways and peripheral sensory feedback mechanisms that connect cervical spinal cord stimulation to the hypoglossal motor nucleus [the brainstem region controlling upper airway muscles] and other respiratory circuits. A key finding from the same research group shows that C4 epidural stimulation alters motor output at the hypoglossal level through both excitatory ascending pathways and inhibitory peripheral sensory feedback — meaning the response is bidirectional and complex, not simply a one-way signal boost. This is a preprint [not yet peer-reviewed] and animal work. The findings have direct implications for designing closed-loop stimulation systems [devices that sense breathing signals and adjust stimulation in real time] that could eventually restore more natural, adaptable breathing in people with cervical SCI.

Why don't nerve fibres in the spinal cord simply regrow after injury? A 2026 study published in Nature by researchers at the Icahn School of Medicine at Mount Sinai identifies the aryl hydrocarbon receptor [AHR] — a protein found in neurons that normally senses environmental signals — as a key molecular brake on axonal regeneration [the regrowth of nerve fibres after damage]. After injury, AHR activates a protective stress response in damaged neurons, tightening protein quality control [proteostasis — the cell's system for managing its protein inventory]. While this protects neurons from immediate stress-induced death, it also downregulates [reduces production of] the growth-promoting proteins that axons need to extend. The research team removed or blocked AHR in mouse models of both peripheral nerve injury and spinal cord injury — either genetically or with pharmacological [drug-based] agents — and found that axons regrew more effectively and motor and sensory function recovered measurably better. Crucially, several AHR-blocking drugs are already in clinical trials for other diseases, including certain cancers, meaning a potential translational pathway may already be partially established. This is currently mouse research; human SCI clinical trials targeting AHR would still be needed. The Mount Sinai team plans to test both AHR-blocking drugs and gene-therapy strategies designed to reduce AHR activity in neurons, in further preclinical and eventually clinical work.

Transplanted cells for spinal cord injury often fail to survive long enough or integrate well enough to make a meaningful difference. A 2026 study in Science China Life Sciences by Yunlong et al. tested whether adding electroacupuncture [electrical stimulation delivered through acupuncture needles] and ordered collagen scaffolds [a structured biological framework that mimics the natural architecture of spinal cord tissue] to neural progenitor cell [NPC] transplantation could change that. Neural progenitor cells are immature cells with the potential to develop into neurons [nerve cells], astrocytes [support cells], or oligodendrocytes [the cells that insulate nerve fibres with myelin]. The study found that electroacupuncture increased local production of neurotrophic factors [growth-promoting proteins such as NT-3 and BDNF] that helped transplanted cells survive and integrate. The ordered collagen scaffold provided a physical roadmap for new nerve fibres to grow along — addressing the disorganised injury environment that usually causes transplanted cells to fail. Together, the three-component approach achieved significantly better motor function recovery in rat SCI models than any single treatment alone. This is an animal study — all results are in rats. Translation to human use would require substantial further development, and the regulatory complexity of combination therapies involving both a device and a cell product adds additional hurdles. It is notable, however, that this directly targets the survival-and-integration failure that has limited cell therapy for SCI.

Spinal cord injury doesn't only damage the cord itself — it sets off a chain reaction that disrupts the gut, derails the immune system, and throws metabolism into disorder. A review paper by Huang et al. in International Immunopharmacology describes the emerging concept of the gut-spinal axis: the two-way communication network connecting the gut's microbial ecosystem and the injured cord. After SCI, loss of normal nerve signals to the gut — known as neurogenic bowel — causes dysbiosis [disruption of the normal gut bacterial community]. This disruption allows harmful bacterial fragments to leak into the bloodstream, triggering systemic immune activation that then worsens neuroinflammation [damaging immune activity] at the injury site. Simultaneously, disruption of metabolic homeostasis [the body's chemical balance], including changes in how fats, sugars, and immune signals are processed, creates conditions hostile to nerve repair. The authors review evidence that restoring gut microbial health — through targeted probiotics, dietary intervention, or faecal microbiota transplant [transferring healthy gut bacteria from a donor] — may reduce neurological damage and improve recovery outcomes. This is a review paper synthesising existing research, not a new experimental study. It points to the gut microbiome as a genuinely underexplored therapeutic target in SCI, though direct human trials of gut-targeted SCI therapies remain in early stages.

SCI triggers two successive crises: an acute inflammatory storm in the first days, followed by chronic failure of neural repair. Most treatments address one phase or the other — not both in sequence. A 2026 study in Chemical Engineering Journal by Ju et al. describes a microenvironment-responsive exosome-hydrogel hybrid system designed to tackle both. Exosomes [tiny vesicles naturally produced by cells, packed with signalling proteins and RNA] are released from the hydrogel in response to the inflammatory signals present at the acute injury site. Once released, they act on immune cells to shift them from a damaging M1 phenotype [attack mode] to a healing M2 phenotype [repair mode]. As inflammation subsides, the hydrogel scaffold continues to support neural regeneration by providing a physical structure for nerve cells to grow along. The study was conducted in animal models, with authors reporting improvements in functional recovery scores. This remains a preclinical study — no human trials have been conducted. Substantial safety testing and clinical development would be needed before use in people. However, this dual-function, sequenced delivery approach is increasingly viewed as the correct strategy in SCI, as single-target treatments have consistently underperformed in clinical translation.

Paralysis after SCI doesn't only affect the limbs — the loss of nerve control extends to internal organs including the bowel, bladder, and stomach, causing significant health complications that represent some of the most debilitating aspects of living with SCI. A 2026 study from MIT's McGovern Institute, published on 31 March, introduces the myoneural actuator [MNA] — a biohybrid device that uses living skeletal muscle [the type that normally moves limbs] surgically rewired so that a computer, rather than the brain, controls it. The MNA is implanted and wrapped around an organ. When the computer sends a signal, the muscle squeezes the organ, restoring a facsimile of normal movement — a process analogous to peristalsis [the rhythmic gut contractions that move food and waste]. In rodent experiments, the team restored squeezing motion in the small intestine. Critically, the system also transmitted sensory signals back toward the brain, suggesting a future implant could allow paralysed organs to communicate their state — such as a stomach conveying hunger or fullness. The authors identify potential applications in neurogenic bowel [loss of gut nerve control in SCI], ileus [post-surgical bowel paralysis], and diabetic enteropathy [gut damage from diabetes]. This is a rodent study; larger-animal and human studies are needed before clinical use. The proof of concept — that living muscle can serve as a fatigue-resistant, computer-controlled actuator inside the body — is genuinely novel and opens a new category of organ restoration technology.

Healing after SCI is a sequence problem: the body needs different treatments at different times, but conventional single-dose therapies can't adapt to an evolving injury environment. A 2026 study in Materials Today Bio by Zhang et al. introduces a spatiotemporal liposome-zwitterionic nanohydrogel system. In practical terms, this is a gel studded with tiny fat-coated capsules that carry therapeutic molecules and release them on a pre-programmed schedule. Zwitterionic materials [materials that carry both positive and negative electrical charges] are notable for biocompatibility and resistance to triggering unwanted immune reactions. The liposomes first release anti-inflammatory compounds in response to the acute-injury microenvironment. As conditions shift over days, the system transitions to deliver immunomodulatory [immune-steering] and neurogenesis-promoting [new neuron growth] signals. The study was conducted in preclinical animal models and reports that the sequential approach addresses the two-phase problem more effectively than single-phase treatments. This is an animal study only — no human trials have been conducted. The complexity of the system is both its therapeutic promise and its regulatory challenge: more components mean more interactions to characterise before clinical use becomes possible.

After spinal cord injury, a dual scar forms at the injury site: a glial scar [made of reactive astrocytes and other support cells] and a fibrotic scar [made of collagen-depositing connective tissue cells]. While these scars initially seal off damage, they quickly become the primary barrier to axonal regeneration [the regrowth of nerve fibres]. A 2026 review by Zhang, Jin, and Ning in Frontiers in Neurology examines growing evidence that mitochondrial dysfunction [failure of the cell's energy-producing organelles] is a key upstream driver of this scarring process. When mitochondria fail after SCI, cells experience energy depletion and a surge of reactive oxygen species [ROS — chemically unstable molecules that damage proteins, fats, and DNA]. This metabolic crisis triggers reactive gliosis [the abnormal over-activation of glial cells], amplifies the inflammatory cascade, and ultimately leads to the dense, inhibitory scar matrix surrounding chronic SCI injury sites. The authors review therapeutic approaches targeting mitochondrial function — including antioxidants [ROS-neutralising molecules], mitochondrial transplantation [an experimental approach to replacing damaged mitochondria with healthy ones], and metabolic modulators. This is a review paper drawing on existing experimental literature, not new experimental data. It frames mitochondrial health as a tractable and time-sensitive therapeutic target, particularly in the acute and subacute injury phases when intervention might prevent scar formation from becoming permanent.

Neuropathic pain — persistent, often burning or stabbing pain caused by nerve damage rather than ongoing tissue injury — affects up to 80% of people living with SCI. A February 2026 review in Experimental Neurology, part of a special issue on central neuropathic pain in SCI, maps the mechanisms driving this condition and critically examines the animal models used to study it. The authors identify several converging mechanisms: central sensitisation [a state in which the spinal cord's pain-processing circuits become abnormally amplified, responding to non-painful signals as if they were painful], neuroinflammation driven by glial cell activation [where microglia and astrocytes shift into inflammatory mode], hyperexcitability of primary sensory neurons [peripheral pain-detecting nerve cells that fire too readily after injury], and structural remodelling of pain circuits in the brain itself. Animal models reviewed include contusion, compression, and transection SCI models in rodents, using von Frey filaments [fine calibrated fibres used to measure mechanical pain sensitivity], thermal testing, and electrophysiological recordings [electrical measurements of pain-processing neuron activity]. The paper flags a critical translational gap: in humans, SCI neuropathic pain is primarily spontaneous or tonic [constant background pain], but animal model measurements almost exclusively use evoked responses [triggered by applied stimuli]. This fundamental mismatch may help explain why so many animal-model successes have failed to produce effective human treatments. This is a review paper — it synthesises existing research rather than presenting new data — but it functions as an important calibration exercise for the field.

Manufacturing consistency is one of the most overlooked but absolutely critical steps between a promising lab therapy and one that can be tested in humans. NurExone Biologic — a Canadian company developing an exosome-based therapy for acute spinal cord injury — announced results from an independent proteomic analysis [a comprehensive study of the protein content of each production batch] conducted at the Technion – Israel Institute of Technology. The analysis evaluated multiple batches of their ExoPTEN exosomes [nano-scale vesicles derived from cells, engineered to carry a genetic payload that suppresses the PTEN gene]. PTEN normally acts as a brake on axon regrowth; suppressing it has been shown in preclinical studies to dramatically enhance nerve regeneration after SCI. The independent analysis confirmed that batches were consistent in composition and biological activity — a requirement of Chemistry, Manufacturing and Controls [CMC] readiness, the regulatory framework governing what must be demonstrated before a drug can be tested in humans. NurExone's planned Phase 1/2a clinical trial is targeted for 2026 and will enrol adult patients with traumatic SCI between spinal levels C5 and T10, classified as ASIA Grade A or B [indicating complete or near-complete injury]. This is a pre-trial announcement — no human data exists yet, and Phase 1 primarily assesses safety rather than efficacy. However, for a therapy with strong preclinical results, clearing the manufacturing consistency hurdle is a meaningful and necessary step toward that first human trial.

In February 2026, Rooprai — a woman with paraplegia [paralysis of the lower body, typically caused by SCI] — took her first steps along a Fort Lauderdale beach wearing an advanced AI-powered robotic exoskeleton. Exoskeletons are wearable robotic frames that support and move the legs through normal walking motions, enabling people with lower-body paralysis to stand upright and walk. The device incorporates artificial intelligence that reads residual nerve and muscle signals, synchronising hip and knee movements to mimic natural gait [the walking pattern]. Unlike earlier exoskeletons that used fixed programmed movements, AI-integrated systems adapt in real time to the user's own signals and terrain. Exoskeletons do not repair the spinal cord; they bypass it by providing external mechanical actuation. Regular exoskeleton use has been shown in some studies to deliver secondary benefits including reduced spasticity [involuntary muscle stiffness and spasms], improved bowel and bladder function, and better cardiovascular fitness — though study quality varies and these benefits are not universal. The technology remains expensive and requires significant training, limiting access. Regulatory approvals for personal exoskeleton use outside clinical settings have expanded in recent years in the US, Australia, and Europe, moving the technology closer to daily-life use for eligible patients.

Note: This study addresses Persistent Spinal Pain Syndrome [PSPS — chronic back and leg pain following spinal surgery that didn't resolve the problem, previously called Failed Back Surgery Syndrome]. While not exclusively an SCI population, spinal cord stimulation [SCS] is a primary treatment modality for SCI-related neuropathic pain, and long-term efficacy and age-related outcome data are directly relevant to the SCI community. SCS involves implanting thin electrode leads near the spinal cord that deliver electrical pulses to modulate pain signals before they reach the brain — essentially interrupting the misfiring pain circuits that produce neuropathic pain. The EV187 study, published in the Neuromodulation journal, assessed 40 patients with PSPS who received SCS therapy, tracking subjective sensory responses using Quantitative Sensory Testing [QST — standardised measurements of response to electrical and mechanical pressure stimuli] at multiple time points. Follow-up ranged from 5 to 11 years — unusually long for this type of study. Pain levels, drug use, and quality of life were assessed throughout. The study found that pain relief persisted over this extended period, and that outcomes were equivalent or better in older patients — countering a clinical concern that SCS is less suitable for elderly patients due to comorbidities or reduced physiological adaptability. Broader data from the US show a 115% increase in SCS trials and a 324% increase in permanent SCS placement in patients over 85 between 2009 and 2018. The EV187 report is a conference abstract-level study; full peer-reviewed data should be consulted for complete conclusions.

The spinal cord is an electrical organ. Nerve signals travel as precisely timed pulses of electrical charge, and the tissue itself maintains a carefully calibrated bioelectrical environment that keeps neurons alive and communicating. When a spinal cord injury occurs, that environment collapses — cells stop firing, the electrical balance breaks down, and a destructive cycle sets in: electrical silence leads to neuronal degeneration, which triggers scar-forming glial cells, which further blocks recovery. A new review in the Journal of Functional Biomaterials asks whether purpose-built biomaterials can reverse this cycle by physically rebuilding the injured cord's electrical environment. What electroconductive biomaterials are The review by Zhang and colleagues focuses on a class of engineered materials called electroconductive biomaterials — substances that conduct electrical signals while remaining safe to implant in living tissue. The most discussed approach involves injectable electroconductive hydrogels: gel-like substances delivered into the injury site by syringe that, once in place, form a matrix conducting electrical signals between surviving nerve cells. The idea is that re-establishing electrical continuity across the injury zone could encourage surviving neurons to fire again and support the regrowth of nerve fibres. How they work Applying controlled electrical signals through the material — exogenous electrical stimulation — can reverse the electrically silent state of neurons and switch on molecular programmes associated with regeneration. The conductive scaffolds can also act as carriers for drugs, growth factors, or transplanted cells, combining physical and biochemical repair approaches in a single implant. Researchers are developing smart versions that respond to the injury environment, releasing therapeutic signals in response to chemical cues. Where this stands For people living with SCI, this field represents a longer-term horizon rather than an imminent clinical option. Most work is preclinical — cell cultures and animal models. The challenge of safely implanting materials into the damaged spinal cord without causing additional harm remains significant, as does demonstrating that any electrical recovery translates to meaningful function in humans. No approved clinical therapies based on electroconductive biomaterials for SCI currently exist, but the field is advancing rapidly.

After a spinal cord injury, the initial physical trauma triggers a secondary injury — a wave of inflammation that continues destroying tissue for hours and days after the event. Controlling this cascade is one of the central challenges in acute SCI treatment. A new systematic review in Brain Sciences examines one promising candidate: etanercept (brand name Enbrel), a drug that blocks TNF-α (tumour necrosis factor-alpha), a key driver of that inflammatory wave. What TNF-α does and how etanercept stops it TNF-α is a protein the body releases in response to injury or infection. After SCI it spikes rapidly, driving secondary damage — activating immune cells, disrupting the blood-spinal cord barrier, and triggering cell death. Etanercept binds to TNF-α and neutralises it before it activates its targets, intercepting the signal before damage escalates. It has been used safely in humans for decades in conditions like rheumatoid arthritis and psoriasis. What the review found The systematic review by Garmo and colleagues, searching studies through December 2025, synthesised preclinical studies of etanercept after SCI. Across included studies, treatment was consistently associated with reduced inflammation, lower levels of TNF-α and IL-1β in tissue and blood, preserved myelin, and improved hindlimb motor function. Some studies found reductions in cell death and neutrophil infiltration — an immune cell type that contributes significantly to secondary injury. The repurposing appeal Etanercept is already approved, well-studied for safety, and available. Drug repurposing can dramatically shorten the path to clinical availability compared to developing a new compound from scratch. However, this review covers animal research only, and the leap from rat SCI models to human trials remains substantial. Timing, dosage, and route of administration in the acute setting would all need to be established before trials could proceed. No human trials of etanercept specifically for SCI are yet underway.

People with spinal cord injury face significantly elevated risk of cardiovascular disease and metabolic conditions like type 2 diabetes. Paralysis reduces active muscle mass, lowering the body's ability to burn glucose and regulate blood fats. Combined with reduced mobility and the physiological changes that follow SCI, this creates a cluster of risk factors — high blood glucose, abnormal lipids, cardiovascular stress — that can develop years before symptoms appear. A new systematic review and meta-analysis in BMC Sports Science Medicine and Rehabilitation examined the full body of evidence on exercise training as a countermeasure. What the analysis covered Khalafi and colleagues searched PubMed, Web of Science, and Scopus from inception to January 2025 — one of the most up-to-date syntheses of this field to date. The analysis examined effects of exercise on glycaemic markers (blood sugar regulation), lipid profiles (cholesterol and triglycerides), and broader cardiometabolic outcomes in adults with SCI. What the evidence shows Exercise training improved multiple markers of metabolic health. Aerobic exercise was particularly effective at improving insulin sensitivity — the body's ability to respond to insulin and clear glucose from blood. Resistance training showed stronger effects on lipid profiles, including reductions in harmful LDL cholesterol and triglycerides. Functional electrical stimulation (FES) cycling, which uses electrical pulses to activate paralysed leg muscles, showed benefits for peripheral insulin sensitivity specifically — engaging metabolic pathways that upper-body exercise alone does not reach. Practical implications The type of exercise matters, and benefits don't require a one-size-fits-all approach. A programme combining aerobic and resistance elements — tailored to injury level and capacity — appears to offer the broadest metabolic benefit. For higher-level injuries where voluntary lower-body exercise isn't possible, FES-based options add a meaningful complement. This is a meta-analysis of existing human clinical studies — a higher level of evidence than single studies alone. Structured exercise programmes should be viewed as a genuine health-protective intervention, not an optional extra.

One of the most persistent obstacles to recovery after spinal cord injury is the secondary injury cascade — a prolonged inflammatory response that continues well beyond the initial trauma. While some immune activity is necessary for repair, in SCI this frequently becomes chronic and destructive. Immune cells called myeloid cells — including macrophages and microglia, the spinal cord's resident immune cells — can persist in an inflammatory state that damages surrounding tissue and limits new connections from forming. A new study in Cells tested whether a two-drug combination could shift this balance. The two agents Propentofylline is a xanthine derivative — related to caffeine — shown in previous research to suppress inflammatory signalling in glial cells. It works by inhibiting pathways that keep immune cells in a pro-inflammatory mode. Interleukin-4 (IL-4) is a naturally occurring cytokine — a chemical messenger — that the body uses to switch immune responses from inflammatory to repair-promoting, previously studied in SCI models as a way to drive macrophages toward a healing rather than destructive state. What the study found Ghosh and colleagues evaluated systemic combination treatment of propentofylline and IL-4 in a spinal cord injury model, measuring effects on myeloid cell populations at the injury site and on functional outcomes. The combination was associated with modulation of lesion-associated myeloid responses — immune cells at the injury site shifted toward a less damaging state — and with improved functional recovery compared to untreated controls. Where this fits Both compounds are known with established research histories, making their combination a relatively straightforward target for further development. However, this is animal research. Translation to human trials would require safety profiling of the combination, dose optimisation, and identification of the treatment window after injury when intervention would be most effective. The findings add to a growing literature on immunomodulation as a strategy for improving SCI outcomes — using drugs or biological signals to deliberately reshape the immune response, rather than blocking it entirely.

Respiratory failure is the leading cause of death in people with cervical spinal cord injuries, and breathing difficulties remain one of the most life-altering consequences of high-level SCI even in those who survive. The phrenic nerve — which drives the diaphragm — receives signals from the brainstem that travel through the spinal cord. When the cord is injured in the cervical region, that pathway is disrupted, weakening or eliminating automatic breathing control. A new study in Experimental Neurology investigated whether targeting specific nerve cells within the spinal cord could strengthen the breathing response in chronic cervical SCI. The cells in question The study by Brezinski and colleagues focused on spinal excitatory interneurons — nerve cells within the cord that don't directly control the diaphragm, but act as amplifiers and relay stations for incoming respiratory signals. When the brainstem sends a breathing signal down the cord, these interneurons boost and shape it before it reaches the motor neurons that drive the breathing muscles. Previous research identified certain cholinergic (acetylcholine-releasing) interneurons as particularly active during hypercapnic ventilatory response — the automatic increase in breathing triggered when blood CO2 rises, a critical safety mechanism. What the researchers found Selectively activating spinal excitatory interneurons enhanced the hypercapnic ventilatory response in chronic cervical SCI. In other words, stimulating these relay cells strengthened the automatic drive to breathe more when CO2 builds up — a response typically blunted after high-level injury. Critically, the approach sustained ventilation improvements in the chronic phase of injury, not just acutely. Why it matters For people with cervical injuries who rely on ventilators or experience breathlessness during exertion, this research points toward a therapeutic target. If specific interneuron populations can be reliably activated — through pharmacology, electrical stimulation, or future optogenetic tools — it may be possible to partially restore respiratory drive without external ventilation. The finding that this works in the chronic phase is particularly relevant for the large population living long-term with cervical SCI. This is preclinical research in an animal model; considerable work remains to translate interneuron activation into clinical practice.

Chronic pain is one of the most common and persistent challenges after spinal cord injury, and opioid medications are frequently prescribed to manage it. But the relationship between pain, opioid use, and mental health in SCI is complex — and a new study in Spinal Cord (Nature) provides some of the clearest data yet on how opioid misuse connects to suicidal ideation in this population. The study and sample Led by James Krause and colleagues at the Medical University of South Carolina, the study drew on self-report data from 1,253 participants enrolled in a longitudinal health outcomes study — one of the largest datasets of its kind in SCI research. Participants answered detailed questions about prescription opioid use, any misuse of opioids, binge drinking, pain levels, depression, and suicidal ideation. The numbers The findings were striking. Self-reported misuse of prescription opioids was associated with 3.51 times the odds of suicidal ideation (OR = 3.51, CI = 1.83–6.72). Using three or more prescription opioids concurrently was associated with 3.53 times the odds (OR = 3.53, CI = 1.50–8.31). For comparison, depression was associated with nearly 6 times the odds (OR = 5.98, CI = 3.60–9.92), and 15 or more painful days per month with more than double the odds (OR = 2.15, CI = 1.24–3.73). Binge drinking did not show a statistically significant relationship with suicidal ideation in this sample. What it means for care These figures highlight an underappreciated compounding risk: chronic pain drives opioid use, opioid misuse compounds psychological distress, and psychological distress elevates suicide risk — all within a population already facing elevated rates of depression and social isolation. The study cannot establish causation, but the associations are robust. The authors argue that pain management, mental health, and suicide risk must be treated as interconnected in SCI care — not as separate concerns. Routine screening for opioid misuse and suicidal ideation, particularly in patients on multiple opioids or with high pain burden, appears warranted.

Tau is a protein perhaps best known from Alzheimer's disease, where it forms tangles inside neurons that contribute to brain cell death. But tau pathology is not exclusive to the brain — research over the past decade has shown that traumatic spinal cord injury also triggers a buildup of a particularly harmful form called cis pT231-tau. This misfolded version disrupts normal cell function and has been found to spread from the injury site to wider areas of the nervous system, amplifying damage beyond the original lesion. A new study in Spinal Cord (Nature) tested whether a targeted antibody against this toxic tau variant could limit that spread. The experimental setup Vahedi and colleagues used adult Wistar rats in which SCI was induced using a standardised weight-drop impactor — a controlled method that produces a consistent moderate-to-severe injury, allowing fair comparison between groups. One group received passive immunotherapy: a pre-made monoclonal antibody precisely engineered to bind cis pT231-tau. The other received a placebo. The results Treated animals showed reduced inflammatory markers at the injury site, enhanced myelin formation, increased levels of NF200 — a protein indicating healthy nerve structure — and lower levels of GFAP, a marker of glial scarring. Behavioural testing using the standardised BBB locomotor scale showed improved motor function in treated animals compared to controls. Why this approach is interesting The significance lies partly in novelty — applying a neurodegeneration approach to acute neurotrauma — and partly in the fact that monoclonal antibody therapies are increasingly well-understood clinically. Antibodies targeting cis pT231-tau have already been developed for traumatic brain injury, and significant investment has already gone into refining anti-tau antibodies in the Alzheimer's field — investment that could accelerate SCI translation if results continue to hold. All findings are from a rat model; human trials of tau-targeting antibodies for SCI have not yet been announced.

When a spinal cord injury severs communication between the brain and body, two distinct problems arise: the ability to move is lost, and the ability to feel — including the sense of where your limbs are in space — is also lost. While previous research has made progress on restoring movement or sensation separately, a new study from Brown University, published in Nature Biomedical Engineering, reports what researchers describe as the first demonstration of both being restored simultaneously in people with complete spinal cord injuries. The study setup Three volunteers with complete SCI — meaning their injuries had fully severed communication pathways through the cord — took part in a two-week in-hospital trial. Surgeons implanted small electrode arrays at two locations along each participant's spinal cord: one below the injury site and one above it. The team, led by associate professor David Borton in collaboration with Rhode Island Hospital and VA Providence Healthcare, tested what each set of electrodes could achieve independently. Two electrodes, two jobs The results showed a clear functional division. Stimulation through the electrodes below the injury activated lower-limb muscles — partially restoring the ability to move the legs. This adds to the now-substantial body of evidence that epidural electrical stimulation (EES) can bypass the injured section and drive surviving spinal circuits directly. What made this study distinctive was the second set of electrodes, placed above the injury. Stimulation through those upper electrodes enabled participants to sense where their legs were located in space — proprioception — even though no voluntary motor signals were passing through. When blindfolded, participants could accurately report leg angle in real time, demonstrating that sensory information could be fed back to the brain via the stimulator. Why both matters Movement without body sense is difficult to control safely — a person who cannot feel where their leg is risks falls, pressure injuries, and inefficient gait. Restoring both together is a step toward the kind of integrated, feedback-controlled movement that allows natural walking. The study is small, and the team notes a longer-term study with more participants is planned. Surgical implantation is required, so this remains an invasive approach for now. Perspective This is an early-phase human clinical study, not yet a randomised controlled trial. It builds on and extends the epidural stimulation work that has generated significant momentum over the past decade. The next phase will need to show whether benefits persist outside a hospital setting and whether they scale to a larger, more diverse population.

A team from Fudan University's Institute of Science and Technology for Brain-Inspired Intelligence, working with surgeons at Zhongshan Hospital and Huashan Hospital in Shanghai, has reported results from a clinical series in which patients with severe spinal cord injuries were able to walk using a system that combines three distinct technologies in concert — earning a US FDA Breakthrough Therapy designation in December 2025. How the triple system works The approach creates a new communication pathway around the injury rather than through it. The first component is a brain-computer interface (BCI) — an EEG array that reads electrical signals from the brain's surface and translates the intention to move into digital commands. The second is an implanted spinal cord stimulator that receives those commands wirelessly and delivers targeted pulses to spinal circuits below the lesion. The third is a lower-limb exoskeleton — a wearable frame that receives the same commands and provides mechanical support for walking. Implantation of two 1-millimetre-diameter probes in the motor cortex and a stimulator in the spine took approximately four hours. What the patients achieved Four patients underwent surgery between January and March 2025. Within 24 hours, patients could move their legs with AI-assisted control. The first patient walked more than five metres using a standing frame by day 15, and could step over moving obstacles — indicating voluntary, intentional movement rather than simple reflex stepping. Based on results from the first three patients, independent leg control and stepping was achieved within two weeks across the series. What makes this distinctive The system uses EEG — non-invasive scalp-surface brain recording — combined with a precisely implanted spinal stimulator. This hybrid tries to combine the lower surgical risk of non-invasive BCI capture with the targeting accuracy that an implanted spinal device provides. The FDA Breakthrough designation allows the Fudan team to work more closely with regulators to accelerate the approval pathway. Limitations to keep in mind This is a four-patient early clinical series with a short follow-up period in a highly specialist surgical setting. Walking was achieved with suspension support, not fully independent ambulation. The system requires ongoing calibration between the brain-reading and spinal stimulation components. Larger trials across varied SCI populations will be needed before this reaches broader clinical use.

There is currently only one approved disease-modifying treatment for spinal cord injury in the world: STEMIRAC, available exclusively in Japan. For the approximately 18,000 people who sustain a new SCI in the United States each year alone — and millions more globally — there are no approved drugs that meaningfully alter the course of injury. A new analysis by market research firm DelveInsight maps six experimental therapies now in clinical development, with the SCI treatment market projected to grow from $354 million in 2025 to $1.4 billion by 2034. NVG-291 — the most clinically advanced NVG-291 (NervGen Pharma) targets PTPσ — a molecular stop signal on nerve cells that the body upregulates after injury, suppressing regeneration. In a Phase 1b/2a trial in people with chronic cervical SCI, NVG-291 produced a three-fold increase in the strength of motor signals reaching a key hand muscle as measured by motor evoked potentials. Improved hand and grip function were also observed, with results presented at the American Spinal Injury Association meeting in June 2025. Antibodies targeting the no-entry signal Elezanumab (AbbVie) blocks RGMa — a protein that acts as a biological no-entry sign in the injured cord, suppressing neuron survival and preventing axons from regenerating across the damaged area. In non-human primate studies it reduced scarring, increased regenerating nerve fibre density, and improved locomotor function over six months. It is currently in Phase 2 trials for acute SCI. MT-3921 (unasnemab, Mitsubishi Tanabe/Osaka University) targets the same RGMa pathway as a parallel effort. Growth factors and stem cells KP-100IT (Kringle Pharma) delivers hepatocyte growth factor — a naturally occurring protein that protects neurons and encourages axon regrowth — directly into the spinal fluid via intrathecal injection. The FDA granted it orphan drug designation in June 2025. Neuro-Cells (Neuroplast) is an autologous stem cell therapy: cells are harvested from the patient's own bone marrow, processed, and re-administered — avoiding the immune rejection risk of donor-derived approaches. NFX88 (Neurofix) rounds out the six. What this means Together these represent antibodies, growth factors, stem cells, and small molecules approaching SCI from different angles and at different stages of injury. None are approved yet, and clinical trial results in SCI notoriously vary between animal models and humans. But the breadth and activity of the current pipeline is significantly greater than at any previous point in SCI research history.

For decades, there was no consensus on how urgently surgeons should operate after an acute spinal cord injury. A new review from the MRC Centre of Restorative Neural Dynamics examines the evolving evidence on surgical timing, and the findings point clearly toward earlier being better, with potentially significant consequences for outcomes. Why every hour counts The central concept is decompression: removing whatever is pressing on the injured spinal cord, whether a fractured vertebra, a displaced disc, or swelling. The longer the cord stays compressed, the more secondary damage accumulates as inflammation, swelling, and cell death extend the original injury. The review draws on a body of clinical research, including the landmark STASCIS study, which found that patients who underwent decompression surgery within 24 hours of injury were nearly twice as likely (relative risk: 2.76) to improve by two or more grades on the standard neurological scale at six months compared to those operated on later. Motor scores also improved by an average of 4.5 additional points in patients who received early surgery. The ultra-early question The more ambitious question the review addresses is whether going even faster, what researchers call 'ultra-early' surgery within 8 to 12 hours of injury, produces additional benefit. The answer is: possibly, but the evidence is not yet strong enough to make a firm recommendation. The studies examining ultra-early windows have been small, and definitions of 'ultra-early' vary across different research groups, making comparisons difficult. No added risk from moving fast Critically, the review found no evidence that operating quickly increases the risk of serious complications. Rates of mortality, infection, and neurological deterioration were similar regardless of whether surgery happened early or late. This removes one of the traditional arguments for waiting. What this means in practice For people with acute spinal cord injuries and their families, the practical message is clear: time matters, and a healthcare system's ability to get patients into surgery quickly may directly affect long-term outcomes. Updated clinical guidelines now recommend early surgery (within 24 hours) as the preferred approach for adult patients with acute SCI. The push toward ultra-early intervention continues as an active area of research.

The Journal of Clinical Medicine, published by MDPI, has opened a special issue titled 'Spinal Cord Injury: New Horizons in Neurorehabilitation and Clinical Management', an invitation for researchers across the field to submit their latest work on SCI treatment and recovery. While this is a call for papers rather than a research finding in itself, special issues like this are worth noting as indicators of where the field is focusing its attention. Broader than you might expect The scope of the issue is notably wide, covering both traumatic SCI (injuries from accidents and falls) and non-traumatic SCI: those caused by conditions like multiple sclerosis, infections, tumours, or degenerative spine disease, a category that often receives less public attention than injury-related paralysis. The issue also invites epidemiological research, meaning studies that examine patterns in how SCI affects populations and data that helps shape healthcare policy and resource allocation. A field in rapid expansion Neurorehabilitation, the speciality focused on helping the nervous system recover or compensate after injury or disease, has expanded significantly in recent years. Advances in robotics, electrical stimulation, brain-computer interfaces, and pharmacological approaches are all contributing to a rapidly evolving picture. A dedicated journal issue drawing together current evidence across these areas serves as a useful snapshot of where the field stands. What it signals for the SCI community The significance is less about any single finding and more about what this represents: mainstream clinical research treating SCI rehabilitation as an active, evolving discipline with enough new work underway to merit its own dedicated publication space. Submissions are ongoing, meaning results from newly completed studies may emerge through this channel in the coming months.

Researchers have taken a closer look at one of the most discussed strategies in spinal cord injury regenerative medicine: combining physical scaffolds with stem cells. They found that the pairing consistently outperforms either component on its own. The analysis reviewed multiple studies examining the use of PLGA scaffolds, a biodegradable synthetic material already widely used in medical implants, loaded or combined with various stem cell types in rat models of spinal cord injury. What is a PLGA scaffold? PLGA stands for poly(lactic-co-glycolic acid). In plain terms, it is a sponge-like structure implanted at the injury site that gives transplanted stem cells somewhere to anchor and grow, rather than simply injecting cells that may not survive or stay in place. The studies reviewed showed that when PLGA scaffolds were used alongside either mesenchymal stem cells (derived from bone marrow or fat tissue) or neural stem cells (capable of developing into nerve tissue), animals showed greater improvements in movement and locomotion than those receiving scaffolds or stem cells alone. The importance of cell combinations The results also pointed to synergies between cell types. Co-transplanting neural stem cells alongside Schwann cells, the cells responsible for maintaining nerve fibres, within a PLGA scaffold appeared to produce better outcomes than using neural stem cells with the scaffold alone. This suggests the repair environment matters as much as any single ingredient. Animal research: promising but not yet human-ready All of this research is at the animal stage. Results in rat models do not automatically translate to humans, and spinal cord injuries in people are significantly more complex than the controlled injury models used in laboratory settings. No human trials were reported in this analysis. That said, systematic reviews like this help researchers identify which combinations are most promising before moving toward clinical testing, and represent continued momentum toward physically rebuilding the injury site.

Nutrition rarely makes headlines in spinal cord injury research, but a March 2026 commentary from clinical specialists draws attention to a body of evidence suggesting that what SCI patients eat, and how well they are supported to eat properly, has a direct and measurable impact on their recovery. The numbers are stark Studies show that 62% of spinal cord injury patients are at risk of malnutrition just three months after their injury, dropping to 40% by the time of hospital discharge. Still a substantial proportion of people leaving inpatient care in a nutritionally compromised state. The consequences are not minor: malnourished patients with SCI have been shown to experience rehabilitation stays that are 52% longer, and a 9.2% higher mortality rate at one year. In a condition where rehabilitation intensity and duration are already central to recovery, these are significant figures. Why SCI changes nutritional needs entirely The reasons for malnutrition after SCI are multiple. The initial injury triggers a metabolic stress response that dramatically increases the body's energy and protein demands, even as the physical and psychological toll of injury can suppress appetite. Over time, SCI changes energy requirements substantially. People with paraplegia typically need around 28 calories per kilogram of body weight per day, while those with tetraplegia need only around 22 calories per kilogram. Without accounting for this reduction, standard hospital feeding guidelines can result in inadvertent over-feeding, which carries its own risks including increased fat mass and metabolic complications. The case for individualised nutrition plans Protein remains critically important, with recommendations suggesting 1.2 to 2 grams per kilogram of body weight per day to support tissue healing, pressure injury prevention, and muscle preservation. The commentary argues for individualised nutrition assessments and rehabilitation plans tailored to each patient's injury level, activity, and recovery stage, rather than one-size-fits-all dietary advice.

Spinal cord stimulation (SCS), the delivery of mild electrical pulses to the spinal cord via implanted electrodes, is already FDA-approved for treating chronic pain from diabetic peripheral neuropathy: the nerve damage that affects the hands and feet of many people with diabetes. A new narrative review published in the journal Cureus in February 2026 asks a more ambitious question. Is SCS actually changing the underlying nerve damage, or just suppressing pain signals? What the review examined Researchers conducted a systematic search of studies published between 1990 and 2025, ultimately analysing 22 papers that examined what SCS does to the structure and function of the nervous system in diabetic neuropathy. They looked beyond pain scores to physical changes in nerve tissue, inflammation markers, blood flow, and brain activity. The five areas examined were: changes to peripheral nerve structure, spinal cord plasticity, changes in brain processing, neuroinflammation, and vascular and metabolic effects. More than a pain switch The overall conclusion was that SCS shows significant promise in actively countering the disease process, modulating inflammation, supporting neuronal repair, and restoring some functional capacity, rather than simply acting as an 'off switch' for pain signals. The specific mechanisms are still being mapped, but the finding that the therapy may influence multiple biological systems simultaneously is notable. Why this matters for SCI research This is relevant to the SCI community because SCS is closely related to epidural stimulation, the technology generating considerable excitement in spinal cord injury research. The two approaches use similar hardware and delivery methods, differing primarily in their targets and parameters. Evidence that electrical spinal stimulation can drive structural nerve repair, rather than just functional compensation, adds a layer of scientific credibility to the broader field.

Natural compounds with medicinal potential rarely make for straightforward stories. Apigenin, a flavonoid found abundantly in parsley, celery, chamomile tea, and other common plants, has been quietly accumulating evidence in spinal cord injury research for several years. Previous studies in rat models showed it reduced scar formation, improved motor function scores after SCI, and appeared to influence key inflammatory pathways. What was not well understood was exactly how. A new 2026 paper in the Journal of Bioenergetics and Biomembranes proposes a specific mechanism: the PTGS2 pathway. What is PTGS2 and why does it matter? PTGS2, also known as COX-2 (cyclo-oxygenase 2), is an enzyme that plays a central role in the body's inflammatory response. When tissues are damaged, COX-2 activity drives the production of prostaglandins, molecules that amplify inflammation and pain. In spinal cord injury, excessive COX-2 activity in the post-injury cascade contributes to the secondary damage that extends beyond the initial trauma site. Inhibiting COX-2 is, in fact, the mechanism behind common anti-inflammatory drugs like ibuprofen, though those drugs cannot easily cross the blood-brain barrier. Why apigenin might be better positioned The study proposes apigenin as a potentially superior natural inhibitor. It can cross the blood-spinal cord barrier more readily than many synthetic drugs, it has a long safety record from food consumption, and it appears to act on PTGS2 specifically in ways that could reduce the neuroinflammatory response without the gastrointestinal or cardiovascular side effects associated with prolonged COX-2 inhibitor use. Where this sits in the research timeline This is a molecular-level mechanistic study, working out the 'why' behind effects already observed in animals. It is not a clinical trial, not a new drug proposal, and not a human study. The journey from identifying a molecular pathway to a clinical treatment is a long one. That said, apigenin's natural origin, safety profile, and existing use in dietary supplements makes it a candidate of genuine practical interest. No human trials have been identified at this stage.

When a limb is amputated, the nerves that once controlled it do not disappear. They remain in the residual limb, still capable of generating signals when the person mentally attempts to move the missing limb. These are sometimes called 'phantom' movements. Until now, reading those signals reliably enough to control a prosthetic leg has been technically extremely difficult: the sciatic nerve carries mixed signals from multiple muscle groups, and separating out individual movement intentions has been beyond existing technology. The breakthrough: reading signals from inside the nerve A team at Chalmers University of Technology in Gothenburg, Sweden, has cleared that hurdle. Their study, published in Nature Communications, describes ultrathin, flexible neural implants inserted into the tibial branch of the sciatic nerve of above-knee amputees. Unlike bulkier electrode designs, the implants pick up signals from inside the nerve itself, what researchers call intraneural recordings, with much finer resolution than surface sensors placed on the skin. The key breakthrough was pairing these recordings with an AI-based system using spiking neural networks, algorithms designed to mimic the way biological neurons communicate, to decode the intended movement. What it can now distinguish The system accurately distinguished between multiple distinct leg and foot movements, including subtle actions like individual toe movements, directly from these nerve recordings. This level of resolution has not been achieved from peripheral nerves in the leg before, and it represents a significant step toward prosthetic limbs controlled by natural, intuitive mental commands rather than consciously triggering predefined movements. Why this matters for SCI research For the SCI community, this research matters because the peripheral nerve is precisely the type of neural tissue that spinal cord stimulation approaches aim to interface with when restoring function below an injury. Understanding how to both read from and write to peripheral nerves with high resolution is a fundamental capability required for more sophisticated neuroprosthetic systems. Testing in functioning prosthetic devices is the next phase.

China's National Medical Products Administration has granted commercial approval, not just research permission but approval for clinical use, to a brain implant designed to restore hand and arm function in people with spinal cord injury. The device, called NEO, was developed by Neuracle Medical Technology based in Shanghai, and its commercial authorisation in March 2026 is the first of its kind anywhere in the world. How the NEO device works NEO is roughly coin-sized and uses eight electrodes, thin wire sensors, implanted into the motor cortex: the area of the brain responsible for planning and initiating movement. When a paralysed user imagines moving their hand, the electrodes pick up the electrical signals generated by that intention, and a computer algorithm decodes them in real time. Those decoded commands are sent to a soft robotic glove worn on the hand, which translates them into actual physical movement. In the 32 patients who participated in the clinical studies underpinning the approval, people who previously could not grasp objects at all were able to independently hold cups, use spoons, and write with assistance from the device. A second Chinese breakthrough: walking within 24 hours Separately, researchers at Fudan University in Shanghai have published results from a small trial involving a different approach: implanting electrode chips in both the brain and the spinal cord to re-establish the neural bridge severed by injury. In that trial, four paralysed patients regained controlled movement of their legs within 24 hours of surgery, and within weeks were able to walk independently with support. This brain-spinal interface approach is distinct from NEO's robotic-glove system but reflects the same underlying strategy: restoring communication across the injury by decoding signals at one end of the broken circuit and re-delivering them at the other. Important caveats These are early cohort studies with small numbers of patients in highly controlled settings with intensive training and support. Access will initially be very limited, and the long-term durability of both devices and outcomes remains to be established. Regulatory approvals in other countries, including the UK and US, would require separate processes. That said, the move from research to commercial availability, even in a single country, is a meaningful threshold crossed.

Following a spinal cord injury, the body undergoes rapid and dramatic changes in composition: muscle mass is lost, fat tissue increases, and metabolic rate shifts significantly depending on the level of injury. These changes are linked to pressure injury risk, cardiovascular health, bone density, and overall rehabilitation capacity. The question of how much a structured nutrition intervention can modify these changes is clinically important, and a 2026 study published in ScienceDirect has attempted to answer it rigorously. What the study tested The study involved people with traumatic spinal cord injury going through inpatient rehabilitation and provided an individualised dietitian-led nutrition programme. Each participant's diet was tailored by a registered dietitian based on their injury level, body measurements, and rehabilitation activities, rather than following a generic hospital diet. Body composition was tracked through the rehabilitation period, measuring changes in fat mass, lean muscle mass, and related parameters. The nuanced headline finding Overall body composition did not change significantly in the sample as a whole. However, when the researchers divided participants by injury characteristics, a clearer picture emerged. The level of injury, whether cervical, thoracic, or lumbar, and the severity, complete versus incomplete, were the primary determinants of body composition change, not changes in diet quality or caloric intake within the trial period. The body's response is heavily dictated by the injury itself, and nutrition alone cannot fully override those effects. What this means in practice This is not a reason to dismiss nutritional support. The evidence remains strong that malnutrition worsens outcomes and that dietitian involvement improves weight management, lipid levels, and pressure injury risk. The finding suggests that body composition targets need to be stratified by injury characteristics, and that realistic goals need to be set accordingly. A person with a complete cervical injury and one with an incomplete lumbar injury will not respond the same way to the same diet programme.

Stem cell therapy has been one of the most anticipated areas of spinal cord injury research for decades. Mesenchymal stem cells (MSCs), a type of multipurpose cell derived from bone marrow, fat tissue, umbilical cord blood, and other sources, have attracted particular attention because of their ability to reduce inflammation, support tissue repair, and potentially encourage nerve regeneration. The volume of research has been enormous. A 2026 narrative review published in Aging and Disease has taken a step back to ask: how well is that research actually working? What the review found The authors searched the ClinicalTrials.gov database and identified approximately 1,600 registered trials associated with MSC therapies across multiple conditions, including spinal cord injury. Their conclusion is candid: while MSCs have shown genuine promise in pre-clinical research, clinical outcomes in humans have been inconsistent, and no standardised, approved MSC-based treatment currently exists for SCI. Why the results are hard to compare The review identifies significant heterogeneity in how trials are designed and conducted: different sources of MSCs, different cell numbers, different delivery methods (some injected into the spinal cord, some via spinal fluid, some intravenously), different timings after injury, and different patient populations. When every study does things differently, comparing results and drawing reliable conclusions becomes extremely difficult. Safety concerns including tumorigenicity and immunogenicity have also not been uniformly addressed across trials. Not a dismissal — a call for rigour The review positions itself as a call for greater standardisation: for the research community to develop consensus protocols, share data more openly, and design trials in ways that generate actionable evidence. Multiple individual trials have reported improvements in motor and sensory function in SCI patients receiving MSC therapy, and the biological rationale remains sound. For people with SCI following the stem cell space, this review is a useful corrective to both excessive pessimism and excessive hype. The potential is real; the standardisation work needed to realise it is ongoing.

One of the most destructive things about a spinal cord injury is not the initial impact: it is what happens in the hours that follow. The body's inflammatory response floods the injury site, killing off nerve cells that survived the original trauma. This 'secondary injury' is a key target for researchers, and a new study in the Journal of Neuroscience has found that a drug already sitting in most hospital crash carts might be able to fight it. The drug and its unexpected benefit The drug is dexmedetomidine, a sedative and analgesic agent routinely used in intensive care units to calm patients. Researchers have now found it has a notable side effect: it causes a drop in core body temperature. This pharmacological hypothermia, or chemically induced cooling, appears to provide significant neuroprotection in rodent models of spinal cord injury. What the animal study showed Animals that received dexmedetomidine shortly after injury showed reduced inflammation at the injury site, less cell death, and meaningfully better functional recovery compared to control animals. The drug appeared to work through multiple pathways simultaneously: suppressing immune over-activation, reducing apoptosis (programmed cell death in damaged cells), and lowering the metabolic demands on surviving nerve tissue during the most vulnerable window after injury. Why the existing approval status matters Because dexmedetomidine is already widely used in hospitals, the path to human trials is potentially shorter than for a brand-new compound. Researchers do not need to start from scratch proving basic safety. Reliably inducing hypothermia in emergency settings is technically complex, and a drug that does it via a simple IV infusion could be considerably easier to deploy than physical cooling methods. Still animal research Rodent results often do not translate directly to humans. Spinal cord injuries in people involve greater anatomical complexity, and timing drug administration in real-world emergency settings is harder to control than in a laboratory. Human clinical trials would need to follow before this could become an acute care intervention.

Spinal cord stimulation (SCS), the delivery of mild electrical pulses to the spinal cord via implanted electrode leads, is already an established therapy for chronic pain. But the technology has largely been binary: the device delivers a fixed pattern of pulses, and clinicians adjust the intensity. The BENEFIT-02 trial, published in the journal Neuromodulation, tested a fundamentally different approach: multiphase stimulation, in which the electrical waveform cycles through multiple distinct phases rather than delivering a single continuous pattern. How the trial was designed The study enrolled 122 participants with chronic low-back or leg pain, of whom 77 were randomised to test either of two multiphase therapy protocols: one running at approximately 600 to 1,500 Hz and one at 300 to 600 Hz, against their existing conventional commercial SCS systems during an 11 to 12-day testing period. Participants essentially served as their own comparisons, switching between standard and multiphase stimulation under trial conditions. The results Both multiphase approaches produced statistically significant reductions in pain. Average numerical rating scale scores fell by 4.3 and 4.7 points respectively from baseline on a 0 to 10 scale. Sixty-four percent of patients reported greater pain relief with multiphase stimulation than with their existing commercial SCS device. Multiphase stimulation also required less power to deliver, which has implications for device battery life and recharging frequency. Why this matters for SCI BENEFIT-02 studied patients with chronic back and leg pain, not spinal cord injury directly. However, SCS technology is relevant to the SCI community for two reasons. First, neuropathic pain is one of the most common and debilitating consequences of SCI, and SCS is an established management tool. Second, this same stimulation technology in its epidural form is the basis for the epidural stimulation research generating excitement in SCI motor recovery. Advances in waveform sophistication feed directly into that broader field.

One of the central challenges in spinal cord injury repair is the hostile environment that forms at the injury site. Within hours of injury, immune cells flood the area, triggering waves of inflammation that kill off surviving nerve cells and prevent repair. Getting therapeutic cells into that environment and keeping them alive long enough to do something useful is a major practical hurdle. A new 2026 study published in Biomaterials Advances has taken a creative approach to the problem. The scaffold: built from blood proteins The researchers developed what they call a PLPH, a platelet lysate-derived macroporous hydrogel. In plain terms: a sponge-like scaffold material made from proteins found in human blood platelets, the cell fragments involved in clotting, engineered to have large interconnected pores. These pores create a microenvironment that mimics biological tissue, giving transplanted cells somewhere to anchor and receive nutrients. Critically, the platelet-origin proteins themselves carry biological signals already familiar to the body. The cells: loaded from fat tissue Into this scaffold, the team loaded ASCs, adipose-derived stem cells harvested from fat tissue. Fat-derived stem cells are a popular research focus partly because they are abundant and relatively easy to harvest, but also because they have natural immunomodulatory properties: they can actively influence the immune system's behaviour. When the PLPH-loaded ASCs were implanted into a mouse model of spinal cord injury, the combination triggered a shift in the behaviour of microglia and macrophages, the brain and spinal cord's resident immune cells. The key result: calming the immune storm The cells switched towards what is called M2 polarisation, an anti-inflammatory pro-repair state, rather than the destructive M1 inflammatory state that typically dominates after injury. The M2/M1 balance is considered a key factor in whether the post-injury environment promotes repair or worsens it. Platelet-derived biomaterials are already used in wound healing contexts, which could smooth regulatory pathways if the approach progresses to human testing.

Two rehabilitation approaches have each shown independent benefit for people with incomplete spinal cord injury, injury where some nerve signals still get through, but they have never been formally tested together. A pilot randomised controlled trial registered in PLOS ONE aims to change that, combining repetitive transcranial magnetic stimulation (rTMS) with functional electrical stimulation (FES) cycling to target lower extremity function. How each therapy works individually Repetitive transcranial magnetic stimulation uses a coil placed against the scalp to generate brief targeted magnetic fields that temporarily stimulate specific areas of the brain, in this case the motor cortex responsible for planning leg movements. Delivering multiple pulses over a session is thought to promote neuroplasticity, the nervous system's ability to reorganise and strengthen connections, in the motor pathways. FES cycling works from the other end: electrodes placed on the legs deliver electrical pulses that cause the paralysed muscles to contract in a coordinated pedalling motion, generating sensory feedback from the legs back toward the brain and potentially reinforcing motor pathways. The combined hypothesis The hypothesis being tested is whether driving activity at both ends of the incomplete circuit simultaneously, stimulating the motor cortex to send signals downward while electrically activating the legs to send signals upward, will produce a synergistic effect on neuroplasticity greater than either approach alone. Where results stand The trial was designed as a pilot to establish feasibility, safety, and the best way to measure outcomes rather than prove effectiveness outright. Recruitment was scheduled to conclude in November 2025, with results expected by approximately July 2026. This is a protocol paper: the trial design and rationale have been published, not the results. Outcome data is imminent.

Arm and hand function is among the most-cited priorities for people living with cervical spinal cord injury, more so in survey after survey than walking. Even partial recovery of hand grip can transform independence. A new multi-centre randomised controlled trial registered in BMJ Open is taking on a fundamental question: does intensive upper limb motor training produce measurable neurophysiological changes, physical reorganisation of the nervous system, alongside functional ones? The science of neuroplasticity being tested The trial focuses specifically on neuroplasticity: the nervous system's ability to adapt and reorganise in response to repeated activity. The well-established principle is that intensive task-specific motor training creates and strengthens neural pathways, both in the brain and in the remaining intact portions of the spinal cord below the injury. The question is whether this can be objectively measured and whether the degree of neurophysiological change predicts functional outcomes. Who is in the trial and what is measured The trial involves participants during the subacute phase after cervical SCI, the weeks and months immediately following injury when neuroplasticity is thought to be at its most active. Participants receive an intensive upper limb training programme and are assessed using neurophysiological measures including cortical and spinal excitability testing, to track whether the nervous system is measurably responding. The multi-centre design across several institutions strengthens the generalisability of the eventual findings. Why this type of trial matters This is a protocol paper: the study design has been published but the trial is ongoing and no results have yet been reported. For the SCI rehabilitation field, this type of investigation matters because it directly connects rehabilitation practice to measurable neurobiological outcomes. If intensive training can be shown to drive specific measurable changes in the nervous system, it strengthens the case for the funding, intensity, and timing of rehabilitation programmes.

This study investigates a biomimetic scaffold composed of hyaluronic acid and collagen, functionalised with anti-inflammatory IL-10, to modulate the glial-immune interface post-SCI. In typical healing, M1-polarised macrophages and reactive A1 astrocytes promote a fibrotic environment leading to a dense chondroitin sulfate proteoglycan (CSPG) scar. This bioengineered approach facilitates a phenotypic switch in macrophages from the pro-inflammatory M1 state to the pro-regenerative M2 state. The shift significantly reduces deposition of Type IV collagen and laminin within the lesion. By 'orchestrating' this immune transition, the scaffold allows for regeneration of GAP-43 positive axons across the lesion epicentre — without encountering the mechanical or chemical barriers of the traditional glial scar. The result is a 'scarless' repair environment that converts the injury site from a permanent roadblock into a growth-permissive bridge.

The Blood-Spinal Cord Barrier (BSCB) is a specialised interface of endothelial cells, pericytes, and astrocyte end-feet that regulates the neural microenvironment. Traumatic SCI induces a biphasic disruption: a rapid primary phase caused by mechanical vessel shearing, followed by a prolonged secondary phase driven by inflammatory cytokines (TNF-α, IL-1β), oxidative stress, and matrix metalloproteinase (MMP) activation. This review maps the time-dependent degradation of tight junction proteins (claudin-5, occludin) and the subsequent infiltration of peripheral immune cells — the 'rioters' that cause further damage once the fence is breached. The paper identifies specific therapeutic windows for barrier stabilisation, arguing that maintaining BSCB integrity is fundamental to any neuroregenerative strategy, as it prevents the toxic lesion environment from spreading to healthy tissue.

Progesterone and its synthetic derivatives are recognised for potent neuroprotective properties, including the ability to modulate GABA receptors, inhibit NF-κB pro-inflammatory signalling, and reduce post-traumatic oedema. This research evaluates the efficacy of hydroxyprogesterone in acute traumatic SCI. Following a standardised regimen of corticosteroids and antibiotics, the addition of hydroxyprogesterone was shown to mitigate perilesional apoptosis (programmed cell death) and reduce expression of pro-inflammatory markers (IL-1β). Results indicated improved motor function scores and reduced secondary axonal loss, suggesting that early hormonal intervention can help stabilise the cellular microenvironment immediately following mechanical insult — acting as a second line of defence against the cascade of self-destruction that unfolds in the hours after injury.

This study maps the structural and functional reorganisation of spinal circuits following a clinically relevant thoracic (T9) contusion injury in murine models. Using retrograde viral tracing and optogenetic stimulation, researchers identified the formation of a 'bypass' circuit mediated by long-descending propriospinal neurons (LDPNs). While the primary corticospinal tract (CST) remains disrupted, LDPNs undergo significant axonal sprouting to form new synaptic connections with lumbar motor neurons below the lesion site. However, kinematic analysis reveals that while this reorganisation supports weight-bearing and locomotion, the resulting gait shows increased variability and decreased inter-limb coordination. The paper concludes that while spontaneous plasticity drives motor recovery, these 'detour' circuits lack the precision of pre-injury supraspinal control — providing a blueprint for therapies that could amplify and refine the body's own rewiring process.

This research focuses on the neuroprotective efficacy of Catalpol (a cyclohexylethanoid glycoside) and Ginsenoside Rg1 in acute SCI. The compounds exert synergistic effects on the NLRP3 inflammasome pathway: specifically, the drug pair significantly inhibits activation of caspase-1 and the subsequent release of pro-inflammatory cytokines IL-1β and IL-18 in the perilesional area. Furthermore, treatment enhanced expression of Nrf2 — a master regulator of the antioxidant response — leading to a marked reduction in malondialdehyde (MDA) levels and increased superoxide dismutase (SOD) activity. The reduction in oxidative stress-mediated lipid peroxidation also preserved the integrity of the blood-spinal cord barrier (BSCB), preventing further infiltration of peripheral immune cells that would otherwise amplify secondary damage. This dual anti-inflammatory and antioxidant action positions these natural compounds as candidates for acute intervention in the critical hours post-injury.

Myelin debris (MD) accumulation is a hallmark of the SCI microenvironment. When macrophages engulf this debris, they become 'foamy macrophages' — cells characterised by lipid overload that often enter cellular senescence, secreting a pro-inflammatory senescence-associated secretory phenotype (SASP) that sustains neuroinflammation and amplifies the secondary injury cascade. This study demonstrates that Tramiprosate (3-amino-1-propanesulfonic acid) restores mitochondrial metabolic flux in these macrophages. By scavenging mitochondrial ROS and enhancing oxidative phosphorylation, Tramiprosate suppresses the ROS-driven senescence programme. Reducing these 'aged' foamy macrophages shifts the injury site from a pro-inflammatory to a pro-resolving environment, facilitating neural tissue preservation and significant functional recovery in experimental models.

Researchers at Northwestern University developed a high-fidelity human spinal cord organoid (hSCO) model using induced pluripotent stem cells (iPSCs) to simulate the cellular and molecular environment of a traumatic SCI. Unlike previous models, these organoids demonstrate complex spatial organisation of motor neurons, interneurons, and astrocytes. The team used these hSCOs to test a supramolecular peptide amphiphile (PA) therapy — colloquially termed 'dancing molecules' — designed to target transmembrane receptors of astrocytes and neurons. The therapy uses high levels of molecular motion to interact with cellular receptors more effectively. Results showed significant downregulation of reactive astrogliosis markers (GFAP and Vimentin) and upregulation of βIII-tubulin, suggesting the therapy suppresses the inhibitory glial scar while promoting neurite outgrowth within a human-derived neural matrix. Because this was tested on human tissue models, it provides a much more accurate preview of how the therapy might work in actual patients.

Vagus Nerve Stimulation (VNS) is emerging as a potent neuromodulatory strategy to enhance structural and functional plasticity following traumatic insult. Mechanistically, VNS delivers precisely timed electrical pulses to the vagus nerve (10th cranial nerve), activating the nucleus tractus solitarius (NTS). This triggers release of key neuromodulators — norepinephrine from the locus coeruleus and acetylcholine from the basal forebrain — across the cortex and spinal cord. When paired with rehabilitative training, these neurochemical surges facilitate Hebbian plasticity, strengthening remaining neural circuits and promoting formation of new synaptic detours around a lesion. This discussion, led by Dr Anjail Sharrief, explores integration of VNS into clinical referral pathways to bridge the gap between acute care and long-term neurorecovery — making it one of the most clinically translatable neuromodulation strategies currently under investigation.

After SCI, many cells undergo pyroptosis — a violent, explosive form of cell death that showers neighbouring cells with inflammatory signals, triggering a destructive chain reaction. This study deploys a dual-layer strategy to stop it. Strategy A (Internal): Stem cells (ADSCs) are 'trained' by feeding them apoptotic bodies — tiny biological packages from dying cells that reprogram the stem cells to suppress the pyroptosis chain reaction from within. Strategy B (External): These engineered cells are embedded in an antioxidant hydrogel that neutralises the reactive oxygen species (the toxic 'sparks') flooding the injury environment. Together, the two strategies reshape the ADSCs-microglia axis — changing the conversation between stem cells and local immune cells from 'danger and destruction' to 'growth and repair.' In preclinical models, this combination produced significant reductions in inflammatory cell death and meaningful functional recovery.

After SCI, microglia (the spinal cord's local immune cells) lock into M1 mode — an attack state that floods the injury site with inflammatory signals and prevents any healing. This study delivers a 'care package' of biological instructions directly to the site to flip microglia to M2 (repair) mode. The payload is FGF21 — a growth factor with strong anti-inflammatory properties — loaded inside exosomes derived from mesenchymal stem cells (MSC-Exo-FGF21). Exosomes are naturally occurring nano-bubbles that cells use to send instructions to one another, making them ideal biological messengers. To ensure the payload doesn't simply wash away, it's encapsulated in a hyaluronic acid hydrogel that stays precisely at the injury site and releases the exosomes gradually. The exosomes act via STAT3/SOCS3 signalling inside the immune cells — activating the molecular 'go' button for repair while keeping the response controlled. In preclinical models: successful M1→M2 shift, quieted neuroinflammation, and significant spinal cord repair and functional recovery.

After SCI, resident immune cells called microglia become 'angry' (M1 state) and flood the injury site with inflammatory signals, causing a damaging second wave that destroys healthy nerve tissue. The goal is to flip these cells to M2 mode — where they act as paramedics, cleaning up debris and releasing healing signals. Kakkalide, a natural isoflavone compound, achieves this switch via mitophagy — the cell's internal trash-disposal system for broken mitochondria. After injury, damaged mitochondria leak toxic reactive oxygen species that keep microglia locked in attack mode. Kakkalide accelerates mitophagy, hauling away these broken power plants before they can poison the cell's behaviour. With the internal toxins cleared, microglia shift to M2 and begin promoting tissue repair. In animal models, Kakkalide treatment produced reduced neuroinflammation, greater nerve cell survival, and improved motor recovery.

After SCI, the injury site's metabolic system goes haywire — inflammatory processes consume huge amounts of cellular energy, accelerating tissue destruction and creating chronic neuropathic pain. miR-107-5p is a microRNA — a tiny genetic 'middle manager' molecule that doesn't build proteins itself but silences the genes that do. It targets the PLOD2/HK2 axis: HK2 is a metabolic pump that feeds the 'fire' of inflammation with energy; PLOD2 is a protein that builds permanent scar barriers preventing nerve regrowth. By silencing both, miR-107-5p simultaneously cuts off the fuel driving inflammation and removes the roadblocks stopping nerve repair. The result in preclinical models was reduced neuroinflammation, restored metabolic balance, and a significant decrease in neuropathic pain — making it a potential dual-action therapeutic target for both the acute and chronic phases of SCI.

After SCI, nerve fibres (axons) cannot regrow because adult nerve cells have a built-in growth brake: a protein called PTEN. This study turns off that brake using siRNA — a genetic 'shut-off notice' that silences the PTEN gene. The challenge is that siRNA is fragile and struggles to enter cells. The researchers solved this with a novel delivery system called a GET (glycosaminoglycan-binding enhanced transduction) peptide — a molecular drone that carries the siRNA directly into the cell's control room. Crucially, this treatment isn't injected freely; it's embedded into a 3D scaffold that sits at the injury site, providing both a physical bridge for nerves to cross and a continuous release of the genetic brake-release signal. The combination of structural support and PTEN silencing produced effective axon regrowth and tissue repair in preclinical models.

After SCI, mitochondria (the cell's power plants) become damaged and leak their DNA (mtDNA) into the cell interior. The cell's innate immune system mistakes this for viral DNA and triggers a massive alarm: the cGAS-STING pathway fires, causing the immune system to flood the injury site with destructive neuroinflammation — even though there is no virus. Zinc blocks this false alarm via two mechanisms. First, it accelerates PINK1-Parkin mitophagy — the cell's trash-disposal system — removing damaged mitochondria before they can leak their contents. Second, it stabilises the BAX/BAK/VDAC1 proteins that form pores in the mitochondrial wall, acting as a molecular 'seal' to prevent mtDNA escape in the first place. With the cGAS-STING alarm silenced, microglia shift from pro-inflammatory to pro-healing behaviour. In animal models, zinc treatment led to reduced neuroinflammation, microglial shift to anti-inflammatory state, and measurable locomotor recovery.

This study introduces a multi-layered scaffold for spinal cord repair. At its core is a 3D-printed scaffold made of Gelatin Methacrylate (GelMA) — a 'bio-ink' that turns solid when exposed to light, providing a physical path for new nerves to follow. The scaffold carries AP39, a mitochondria-targeted hydrogen sulphide (H₂S) donor. In tiny, controlled doses, H₂S protects the cell's power-producing mitochondria from breaking down after injury. Because H₂S is a gas that disappears quickly, the researchers encapsulated AP39 inside liposomes — tiny fat-bubble capsules that act as timed-release carriers, keeping the healing gas at the injury site for days. The system activates the PI3K/AKT survival pathway, preventing glial scar formation (the hard wall that blocks nerve regrowth) and allowing axons to bridge the injury and restore brain-to-limb communication.

Extracellular vesicles (EVs) are microscopic bubbles that cells release into the body to send messages to one another. They contain proteins and genetic material that act as biomarkers — biological signatures providing a 'snapshot' of what is happening inside the injured spinal cord. Because SCI outcomes vary greatly between patients, doctors currently struggle to predict recovery accurately. By analysing these bubbles in blood or spinal fluid, researchers aim to achieve more accurate early diagnosis — identifying injury severity faster — and a better prognosis, allowing treatments to be tailored to each individual. This review is a state-of-the-art summary of where the field stands, highlighting the most promising EV-based markers being investigated for clinical use.

Selenium is a vital nutrient for brain health. This study focuses on Selenomethionine (SeMet), a highly bioavailable form found naturally in food. After a spinal cord injury, nerve cells often undergo apoptosis — a form of 'programmed cell death' where the cell triggers its own destruction in response to trauma. Separately, the injury disrupts iron balance inside cells, triggering ferroptosis — a distinct death pathway driven by iron-catalysed oxidative damage. SeMet works by inhibiting oxidative damage: it acts as a chemical shield that neutralises the reactive molecules driving both death pathways. By blocking these two 'self-destruct switches' simultaneously, SeMet allows more nerve cells to survive the initial trauma — preserving more motor and sensory function in the critical hours after injury. This positions it as a potential low-cost, nutritionally accessible neuroprotective intervention.

After a spinal cord injury, nerves fail to form functional synaptic connections — the electrical 'handshakes' nerves use to communicate. This study introduces a bioactive conductive hydrogel incorporating Ti₃C₂Tₓ (MXene) and Cerium (Ce) nanoparticles. The hydrogel can carry electricity, helping nerves stay connected across the injury site. Critically, it performs ROS scavenging — acting like a molecular 'vacuum cleaner' that removes reactive oxygen species, the toxic molecules responsible for ongoing cell damage after injury. It also provides mitochondrial regulation, keeping the cell's energy-producing batteries healthy and productive. By simultaneously conducting nerve signals, neutralising toxins, and protecting cellular energy supply, this hydrogel creates the conditions the spinal cord needs to physically and electrically repair itself.

Following traumatic injury, cells become cluttered with toxic waste and damaged components, which eventually kills them. 20-Deoxyingenol (20-DOI) works by activating TFEB — the 'master regulator' of the cell's waste-disposal system known as Autophagy. When TFEB is switched on, the cell begins a 'deep clean,' breaking down the dangerous byproducts that lead to Ferroptosis (the iron-driven cell death also targeted in the nano-patch study). By keeping cells clean and operational, 20-DOI prevents the secondary 'wave' of damage that typically occurs in the days following an injury, preserving more healthy tissue and functional movement. The compound represents a promising early-stage pharmacological intervention for acute SCI.

Nerves are like electrical wires — they need insulation to work. This insulation is called Myelin, and after an injury it is often stripped away, leaving nerves unable to send signals. This study found that Electroacupuncture (EA) at specific points (Dazhui and Mingmen) activates the NRG1-ErbB4 pathway. NRG1 (Neuregulin-1) is a signalling protein that acts as a 'construction foreman,' telling the body to build more insulation. ErbB4 is the specific 'docking station' on the cell that receives these orders. By stimulating this pathway, the treatment successfully promoted Myelin Regeneration — re-insulating the damaged nerve fibres — which led to significantly improved walking ability in laboratory models.

Methotrexate is typically used for cancer or arthritis, but in SCI research it is studied for its ability to suppress the overactive immune response that attacks healthy nerves after injury. However, this review highlights a critical conflict: while it is neuroprotective in rat models, it can be neurotoxic in human clinical data — in some cases causing Myelopathy, a condition that actually causes additional spinal cord damage. The conclusion is that while the drug's anti-inflammatory power is real, researchers must find a way to deliver it with greater precision — possibly through targeted nano-delivery systems — to avoid damaging the very nerves they are trying to save.

After a spinal cord injury, the body creates a Glial Scar. While this scar initially protects the injury site, it eventually becomes a hard chemical wall that prevents nerves from ever regrowing. This study identified Luteolin as a compound that targets PTGS2 (an inflammation-driving enzyme) and the NF-kB pathway — the body's main inflammation master switch. By blocking these pathways, Luteolin reduces the activity of Astrocytes (the cells that build the scar). This results in a much softer, thinner scar, allowing for Axonal Regeneration — the actual physical regrowth of nerve fibres — across the injury site. The study reported significantly improved motor function scores and presents Luteolin as a promising low-toxicity therapeutic candidate.

When a cervical (neck-level) injury occurs, the hands often lose function entirely. Surgeons use two main 'rewiring' techniques. Nerve Transfers re-route a healthy, redundant nerve from above the injury — like the brachialis nerve in the arm — and connect it to a non-working nerve below. This allows the brain to eventually communicate with the hand again, resulting in natural biomechanics (fluid, complex finger movement). Tendon Transfers are a mechanical fix: a working muscle such as the brachioradialis in the forearm is physically detached and reconnected to a different tendon to create a specific movement like a pinch or grip. The review found that nerve transfers are superior for fine motor control, while tendon transfers are better for generating the raw strength needed for heavy grasping — pointing toward patient-specific surgery planning.

Scientists took Exosomes (nano-sized delivery bubbles) from orange juice and enhanced them with Magnesium and Carbon Dots. Orange juice exosomes are naturally rich in Vitamin C and Flavonoids — powerful antioxidants. When applied as a patch to the spinal injury site, they trigger M2 Macrophage Polarisation. In simple terms: the immune system has 'angry' cells (M1) that cause damage and 'healer' cells (M2) that repair tissue. This orange juice patch flips the immune response into 'healer mode' (M2), leading to significantly more Axonal Regeneration (new nerve growth) and improved movement scores. The approach offers a low-cost, low-toxicity biological alternative to synthetic drug delivery.

This study addresses one of the most destructive processes after a spinal injury: Ferroptosis — think of it as 'biological rust.' It is a newly discovered type of iron-dependent cell death where the cell's outer membrane breaks down due to a chemical imbalance. The researchers created a polyzwitterionic hydrogel — a synthetic, jelly-like scaffold that is biocompatible (the body doesn't reject it) and electrophysiologic (it can transmit electrical signals between nerves). Inside this gel, they placed engineered exosomes (tiny biological delivery bubbles) loaded with siNox4. NOX4 is an enzyme that acts as a 'fire-starter' for oxidative stress and cell death. By silencing it with siNox4, the treatment puts out the fire — preventing the rusting of healthy neurons while providing a physical and electrical bridge for new nerves to grow across the injury site.

This research provides a step-by-step roadmap for Systematic Rehabilitation Nursing, emphasising that recovery isn't just about the legs — it centres on the Trunk. Stage 1 (Acute) focuses on axial turning and posture to prevent pressure ulcers and joint stiffening. Stage 2 (Recovery) transitions to Sitting Balance Training, moving patients from propped-up to unsupported sitting. Stage 3 (Independence) focuses on Transfer Training — mastering the move from bed to wheelchair — and Wheelchair Control, including handling slopes and obstacles. The framework positions nurses as coordinators ensuring the patient's body is physically ready for the high-intensity work required in later rehabilitation stages.

One of the most overlooked complications of SCI is sudden, massive loss of bone density in the legs, because they no longer bear weight. This study tested a combination of Thymoquinone (the active compound in Black Seed oil) and Coenzyme Q10. The therapy works by enhancing the Wnt/β-catenin signalling pathway — the primary 'on/off' switch for new bone building in the body. By keeping this switch active and simultaneously boosting the body's antioxidant defences, the combination prevented the skeletal degradation that normally follows paralysis. This is a critical finding for long-term health: if a cure for paralysis is found, the patient's bones need to be strong enough to support walking again.

For those with injuries at the C1-C4 level, breathing independently is the number one clinical priority. This cohort study examined who was able to liberate from the ventilator (breathe without a machine) and decannulate (have their breathing tube removed). The findings showed that the length of the initial ICU stay and the early presence of a cough reflex were the strongest predictors of success. This data allows doctors to set realistic expectations with families and helps respiratory therapists decide precisely when to begin 'weaning' a patient off the machine — giving them the best possible chance of regaining independent breathing.